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Health-related quality of life in glomerular disease
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There is scant literature describing the effect of glomerular
disease on health-related quality of life (HRQOL). The Cure
Glomerulonephropathy study (CureGN) is an international
longitudinal cohort study of children and adults with four
primary glomerular diseases (minimal change disease, focal
segmental glomerulosclerosis, membranous nephropathy,
and IgA nephropathy). HRQOL is systematically assessed
using items from the Patient-Reported Outcomes
Measurement Informative System (PROMIS). We assessed
the relationship between HRQOL and demographic and
clinical variables in 478 children and 1115 adults at the
time of enrollment into CureGN. Domains measured by
PROMIS items included global assessments of health,
mobility, anxiety, fatigue, and sleep impairment, as well as
a derived composite measure incorporating all measured
domains. Multivariable models were created that explained
7 to 32% of variance in HRQOL. Patient-reported edema
consistently had the strongest and most robust association
with each measured domain of HRQOL in multivariable
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analysis (adjusted b [95% CI] for composite PROMIS score
in children, -5.2 [-7.1 to -3.4]; for composite PROMIS score in
adults, -6.1 [-7.4 to -4.9]). Female sex, weight (particularly
obesity), and estimated glomerular ﬁltration rate were also
associated with some, but not all, domains of HRQOL.
Primary diagnosis, disease duration, and exposure to
immunosuppression were not associated with HRQOL after
adjustment. Sensitivity analyses and interaction testing
demonstrated no signiﬁcant association between disease
duration or immunosuppression and any measured domain
of HRQOL. Thus, patient-reported edema has a consistent
negative association with HRQOL in patients with primary
glomerular diseases, with substantially greater impact than
other demographic and clinical variables.
Kidney International (2019) 95, 1209–1224; https://doi.org/10.1016/
j.kint.2018.12.018
KEYWORDS: edema; health-related quality of life; patient-reported outcomes; primary glomerular disease
Copyright ª 2019, International Society of Nephrology. Published by
Elsevier Inc. All rights reserved.

T

he 4 major primary glomerular diseases—minimal
change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and
IgA nephropathy (IgAN)—represent some of the most
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common causes of chronic kidney disease managed by nephrologists. These diseases are a signiﬁcant cause of end-stage
kidney disease across all ages in the United States, accounting
for 6.6% of all cases and up to 13.1% of cases in children.1
The treatment of glomerular diseases is associated with complications including infections, thromboembolism, and acute
kidney injury, and result in frequent hospitalizations and signiﬁcant burden on the health care system.2 Although the
medical burden of glomerular diseases is well known, little
has been published about their impact on the quality of life
of affected patients. Understanding the perspective of the patient can help optimize care, education, and anticipatory
counseling provided by health care teams.3
Both the National Institutes of Health and the Food and
Drug Administration have set forth an imperative to examine
the full disease experience of patients and patient-reported
outcomes (PROs) in medical decision making, research, and
clinical trials.4,5 Although research has advanced the understanding of health-related quality of life (HRQOL) in conditions such as advanced kidney failure,6 there is a paucity of
data describing HRQOL in the primary glomerular diseases.
Cross-sectional studies of children with nephrotic syndrome
have included a description of HRQOL using instruments
such as Patient-Reported Outcomes Measurement Information System (PROMIS) and PedsQL, ﬁnding substantial impairments in quality of life in areas such as social functioning
and pain interference, with associations noted with disease
duration and speciﬁc therapies.7,8 Quality-of-life impairments
also have been shown in small studies of adults with
nephrotic syndrome.9–11 Very little is known about HRQOL
in patients with IgAN or MN, and scant effort has been made
to comprehensively identify variables associated with HRQOL
broadly in glomerular diseases.
The Cure Glomerulonephropathy study (CureGN) is a
multicenter longitudinal cohort study of children and adults
with the 4 major primary glomerular diseases (MCD, FSGS,
MN, and IgAN). The aims of the current study are to describe
the HRQOL and to determine the variables associated with
HRQOL at enrollment in the CureGN cohort across age and
disease groups.
RESULTS
Demographics

A Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) ﬂow diagram of included patients
from CureGN is shown in Figure 1. There were 478 children
and 1115 adults with HRQOL data available at enrollment.
These cohorts are described in Tables 1 and 2, respectively. An
additional 42 children and 18 adults did not have HRQOL
data available, representing only 8% and 2% of the available
pediatric and adult CureGN participants (Supplementary
Tables S1 and S2). The distribution of diseases differed between the pediatric and adult cohorts. From the IgAN cohort,
IgA vasculitis (IgAV, formerly known as Henoch-Schönlein
purpura) was analyzed separately. The proportion of children
with MCD was greater than adults (28% vs. 13%,
1210
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respectively), as was the proportion of children with IgAV
(16% vs. 5%). The proportions of children and adults with
FSGS (24% vs. 24%) and IgAN (26% vs. 31%) were similar.
There were fewer females than males in both the pediatric and
adult cohorts. Racial and ethnic distributions were similar for
children and adults, two thirds of participants were white and
nearly 90% were of non-Hispanic ethnicity. There were
substantial differences in racial distribution among the diagnoses, with black participants more likely to have FSGS and
less likely to have IgAN or IgAV. Thirty percent of children
and 37% of adults were classiﬁed as obese.
Clinical features

Only 32% of children reported any edema at presentation, as
opposed to 58% of adults. Among both children and adults,
edema was less common in IgAN or IgAV. The median urine
protein:creatinine ratio (UP:C) was 0.5 (interquartile range
[IQR], 0.1–2.2) for the pediatric cohort and 1.9 (IQR, 0.6–
4.4) for the adult cohort. Thirty-six percent of the pediatric
cohort, but only 16% of the adult cohort, had a UP:C less
than 0.3, indicating relatively more pediatric participants were
in complete disease remission at the time of assessment.
Accordingly, the median estimated glomerular ﬁltration rate
(eGFR) was 97 ml/min per 1.73 m2 (IQR, 82–116 ml/min per
1.73 m2) for children but 68 ml/min per 1.73 m2 (IQR, 41–96
ml/min per 1.73 m2) for adults, and 91% of children with
available data had an eGFR greater than 60 ml/min per 1.73
m2, while in adults this proportion was 56%. A minority of
both children and adults had been exposed to immunosuppressive therapy (IST) within 60 days before enrollment (28%
and 23%, respectively). Among those recently exposed to IST,
corticosteroids were the most common agent used in both
cohorts and among all diseases.
Baseline HRQOL assessed by PROMIS

Baseline HRQOL measures are summarized in Figure 2, which
shows the distribution of scores across the 4 PROMIS domains
measured in children and the 5 PROMIS domains measured in
adults, as well as the calculated composite scores. Means and
SDs are reported in the ﬁgures. The shapes of the distributions
reﬂect the number of questionnaire items used for each
domain. For example, anxiety and sleep impairment were each
measured by a single 5-item Likert scale, thus those distributions have 5 discrete peaks and resulted in skewed values.
Edema and HRQOL

To identify potential predictors of HRQOL, multivariable
linear regression models were created for each PROMIS
domain. Initial analyses showed that the presence of any
edema was associated strongly with worse HRQOL across
both children and adults for every PROMIS domain. Using
negative numbers to indicate worse HRQOL, adjusted linear
regression coefﬁcients (b) for the pediatric domains were as
follows: –3.6 (95% conﬁdence interval [CI], –5.4 to –1.8) for
global health, –4.4 (95% CI, –6.1 to –2.7) for mobility, –6.4
(95% CI, –8.6 to –4.2) for fatigue, –2.1 (95% CI, –3.4 to –0.9)
Kidney International (2019) 95, 1209–1224
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Figure 1 | STROBE ﬂow diagram of included patients. ESKD, end-stage kidney disease; NEPTUNE, NEPhrotic syndrome sTUdy NEtwork;
PROMIS, Patient-Reported Outcomes Measurement Information System; STROBE, Strengthening the Reporting of Observational Studies in
Epidemiology.
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Table 1 | Description of pediatric CureGN patients with PROMIS data at enrollment
Variables
N (%)
Median age, yr (IQR)
Female, n (%)
Race, n (%)
Black/African American
White/Caucasian
Other
Hispanic, n (%)
Obese, n (%)
Hematuria, n (%)
Any edema, n (%)
Median UP:C (IQR)
<0.3, n (%)
0.3–1.5, n (%)
1.5–3.5, n (%)
>3.5, n (%)
Missing, n (%)
Median eGFR (IQR)
<30, n (%)
30–60, n (%)
60–90, n (%)
>90, n (%)
Missing, n (%)
IST within 60 days, n (%)
None
Corticosteroids alone
Other IST
Past 60 days median prednisone dose, mg/kg/d (IQR)
IST type, n (%)
Corticosteroids
CNI
Cyclophosphamide
Mycophenolate
Rituximab
Median disease duration, mo (IQR)

All

MCD

FSGS

MN

IgAN

IgAV

115 (24)
14 (12–16)
55 (48)

28 (6)
15 (13–16)
16 (57)

126 (26)
14 (11–16)
48 (38)

75 (16)
12 (9–14)
25 (33)

478 (100)
13 (10–15)
202 (42)

134 (28)
12 (9–14)
58 (43)

92
319
67
49
142
137
152
0.5
170
129
55
76
48
97
15
26
116
294
25

(19)
(67)
(14)
(10)
(30)
(29)
(32)
(0.1–2.2)
(36)
(27)
(12)
(16)
(10)
(82–116)
(3)
(5)
(24)
(62)
(5)

35
77
22
12
33
13
54
0.4
55
25
15
24
15
111
1
6
19
98
10

(26)
(57)
(16)
(9)
(25)
(10)
(40)
(0.1–2.7)
(41)
(19)
(11)
(18)
(11)
(93–127)
(1)
(4)
(14)
(73)
(7)

43
59
13
12
42
6
40
1.2
31
27
19
20
18
90
10
16
26
55
6

(37)
(51)
(11)
(10)
(37)
(5)
(35)
(0.2–2.8)
(27)
(23)
(17)
(17)
(16)
(60–108)
(9)
(14)
(23)
(48)
(5)

8
15
5
6
13
2
17
3.2
3
7
3
13
2
97
1
1
7
18
1

(29)
(54)
(18)
(21)
(46)
(7)
(61)
(0.9–7.4)
(11)
(25)
(11)
(46)
(7)
(87–114)
(4)
(4)
(25)
(64)
(4)

4
103
19
14
29
89
22
0.3
55
41
12
9
9
94
2
3
46
69
6

(3)
(82)
(15)
(11)
(23)
(71)
(17)
(0.1–0.8)
(44)
(33)
(10)
(7)
(7)
(81–109)
(2)
(2)
(37)
(55)
(5)

2
65
8
5
25
27
19
0.5
26
29
6
10
4
101
1

345
75
58
0.2

(72)
(16)
(12)
(0.1–0.5)

90
22
22
0.2

(67)
(16)
(16)
(0.1–0.5)

81
16
18
0.1

(70)
(14)
(16)
(0.1–0.3)

16
5
7
0.2

(57)
(18)
(25)
(0.1–0.5)

107
16
3
0.4

(85)
(13)
(2)
(0.1–0.7)

51
16
8
0.3

(68)
(21)
(11)
(0.2–0.5)

105
35
1
19
8
18

(22)
(7)
(0)
(4)
(2)
(5–42)

31
15
0
5
4
34

(23)
(11)
(0)
(4)
(3)
(13–61)

25
11
0
6
4
18

(22)
(10)
(0)
(5)
(3)
(6–45)

10
7
0
0
0
6

(36)
(25)
(0)
(0)
(0)
(1–17)

(13)
(1)
(0)
(2)
(0)
(4–34)

22
1
1
6
0
9

(29)
(1)
(1)
(8)
(0)
(3–20)

17
1
0
2
0
15

(3)
(87)
(11)
(7)
(33)
(36)
(25)
(0.2–1.4)
(35)
(39)
(8)
(13)
(5)
(90–121)
(1)

18 (24)
54 (72)
2 (3)

CNI, calcineurin inhibitor; eGFR, estimated glomerular ﬁltration rate; FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; IgAV, IgA vasculitis; IQR, interquartile
range; IST, immunosuppressive therapy; MCD, minimal change disease; MN, membranous nephropathy; UP:C, urinary protein:creatinine ratio.

for anxiety, and –5.2 (95% CI, –7.1 to –3.4) for the composite
score; and adult domains were as follows: –6.8 (95% CI, –8.0
to –5.6) for global physical health, –3.9 (95% CI, –5.0 to –2.8)
for global mental health, –5.8 (95% CI, –7.0 to –4.5) for fatigue, –4.8 (95% CI, –5.8 to –3.8) for sleep impairment, –2.9
(95% CI, –3.9 to –1.9) for anxiety, and –6.1 (95% CI, –7.4 to
–4.9) for the composite score (Figure 3). Because of the
strength of this association, edema was characterized further
by combining aspects of location and severity to create
ordinal variables, and these variables were entered into
multivariable models. The worst reported edema severity for
each diagnostic group in children and adults is shown in
Figure 4. Compared with children, adults reported more severe edema scores and were less likely to report no edema,
even within diseases. The full distribution of edema scores by
diagnosis and age group is available in Supplementary
Tables S3 and S4.
The results of the ﬁnal multivariable analyses are summarized in Tables 3 and 4 (unadjusted univariable analyses
are shown in the Supplementary Tables S5–S15). In the ﬁnal
models, worst edema remained robustly associated with every
HRQOL domain in adults: using negative numbers to indicate
1212

worse HRQOL, linear coefﬁcients b were as follows: –1.6
(95% CI, –2.2 to –1.1) for global physical health, –0.7 (95%
CI, –1.3 to –0.1) for global mental health, –0.6 (95% CI, –0.3
to –1.0) for anxiety, –2.1 (95% CI, –1.7 to –2.5) for fatigue,
–1.1 (95% CI, –0.7 to –1.4) for sleep impairment, and –1.6
(95% CI, –2.0 to –1.2) for the composite score. Various
edema variables were those most associated with HRQOL
domains in children as well (Table 3). For certain domains,
speciﬁc locations of edema (e.g., face, leg, genitals) had a
residual association beyond worst edema, although the majority of the variance explained in most models was from
worst edema. Increasing severity of edema was associated with
stepwise worsening HRQOL in most domains for both children and adults (Figure 5), and h2 values were improved
(indicating greater variance explained) by using the ordinal
worst edema instead of the binary any edema. Despite the use
of various edema terms, none of the ﬁnal multivariable
models showed evidence of signiﬁcant multicollinearity (as
indicated by the variance inﬂation factors in Tables 3 and 4, in
which a variance inﬂation factor > 4 indicates potential
collinearity and a variance inﬂation factor > 10 indicates
multicollinearity requiring correction).
Kidney International (2019) 95, 1209–1224
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Table 2 | Description of adult CureGN patients with PROMIS data at enrollment
Variables
N (%)
Median age, yr (IQR)
Female, n (%)
Race, n (%)
Black/African American
White/Caucasian
Other
Hispanic, n (%)
Obese, n (%)
Hematuria, n (%)
Any edema, n (%)
Median UP:C (IQR)
<0.3, n (%)
0.3–1.5, n (%)
1.5–3.5, n (%)
>3.5, n (%)
Missing, n (%)
Median eGFR (IQR)
<30, n (%)
30–60, n (%)
60–90, n (%)
>90, n (%)
Missing, n (%)
IST within 60 days, n (%)
None
Corticosteroids alone
Other IST
Past 60 days median prednisone dose, mg/kg/d (IQR)
IST type, n (%)
Corticosteroids
CNI
Cyclophosphamide
Mycophenolate
ACTH
Rituximab
Median disease duration, mo (IQR)

All

MCD

FSGS

MN

IgAN

IgAV

1115 (100)
44 (31–58)
482 (43)

141 (13)
43 (26–58)
77 (55)

271 (24)
42 (29–56)
134 (49)

305 (27)
55 (43–65)
110 (36)

344 (31)
40 (30–51)
140 (41)

54 (5)
35 (25–48)
21 (39)

165
747
203
153
415
131
643
1.9
179
284
237
329
86
68
151
328
290
323
21

(15)
(67)
(18)
(14)
(37)
(12)
(58)
(0.6–4.4)
(16)
(25)
(21)
(30)
(8)
(41–96)
(14)
(29)
(26)
(29)
(2)

21
95
25
11
52
3
91
1.8
42
19
14
51
15
93
6
23
38
70
4

(15)
(67)
(18)
(8)
(37)
(2)
(65)
(0.1–6.8)
(30)
(13)
(10)
(36)
(11)
(63–114)
(4)
(16)
(27)
(50)
(3)

81
144
46
47
109
8
175
2.6
23
63
76
90
19
57
54
89
63
60
4

(30)
(53)
(17)
(17)
(40)
(3)
(65)
(0.9–4.9)
(8)
(23)
(28)
(33)
(7)
(34–86)
(20)
(33)
(23)
(22)
(1)

45
218
42
27
115
10
212
3.3
31
49
65
137
23
72
31
81
101
86
6

(15)
(71)
(14)
(9)
(38)
(3)
(70)
(1.1–5.9)
(10)
(16)
(21)
(45)
(8)
(46–94)
(10)
(27)
(33)
(28)
(2)

17
245
82
61
113
98
139
1.0
70
131
73
43
27
57
55
125
75
83
6

(5)
(71)
(24)
(18)
(33)
(28)
(40)
(0.4–2.2)
(20)
(38)
(21)
(13)
(8)
(38–88)
(16)
(36)
(22)
(24)
(2)

1
45
8
7
26
12
26
1.0
13
22
9
8
2
84
5
10
13
24
1

(2)
(83)
(15)
(13)
(48)
(22)
(48)
(0.3–1.9)
(24)
(41)
(17)
(15)
(4)
(51–112)
(9)
(19)
(24)
(44)
(2)

860
119
136
0.1

(77)
(11)
(12)
(0.1–0.3)

81
27
33
0.2

(57)
(19)
(23)
(0.1–0.5)

204
28
39
0.1

(75)
(10)
(14)
(0.1–0.5)

247
17
41
0.1

(81)
(6)
(13)
(0.1–0.1)

296
31
17
0.1

(86)
(9)
(5)
(0.1–0.3)

32
16
6
0.2

(59)
(30)
(11)
(0.1–0.3)

160
79
14
31
3
13
16

(14)
(7)
(1)
(3)
(0)
(1)
(5–40)

35
21
2
7

(25)
(15)
(1)
(5)

(10)
(1)
(0)
(3)
(0)
(0)
(4–41)

20
0
1
4
0
1
10

(37)
(0)
(2)
(7)
(0)
(2)
(2–25)

4 (3)
20 (7–41)

39
28
0
8
2
3
21

(14)
(10)
(0)
(3)
(1)
(1)
(6–45)

31
25
11
0
1
5
14

(10)
(8)
(4)
(0)
(0)
(2)
(5–36)

35
5
0
12
0
0
15

ACTH, adrenocorticotropic hormone gel; CNI, calcineurin inhibitor; eGFR, estimated glomerular ﬁltration rate; FSGS, focal segmental glomerulosclerosis; IgAN, IgA nephropathy; IgAV, IgA vasculitis; IQR, interquartile range; IST, immunosuppressive therapy; MCD, minimal change disease; MN, membranous nephropathy; UP:C, urinary
protein:creatinine ratio.

Other associations with HRQOL

In both children and adults, female sex was associated with worse
anxiety and fatigue, as well as worse composite HRQOL scores. In
adults, female sex also was associated with worse global assessment of physical (but not mental) health. Weight status in children was associated signiﬁcantly with global assessment of health,
with a type I h2 comparable with that of worst edema (indicating
those 2 variables explained a similar proportion of variance for
that domain). Among children, weight status also was associated
with fatigue, mobility, and composite HRQOL. In adults, weight
status was associated signiﬁcantly with global assessment of
physical health only.
Typical biological measures of disease activity including eGFR
and proteinuria seemed to have a minimal relationship to
HRQOL in multivariable models. For pediatric HRQOL, neither
eGFR nor UP:C contributed signiﬁcantly to any of the multivariable models. For adult HRQOL, eGFR was associated
signiﬁcantly with global assessments of physical health and
mental health, fatigue, and sleep impairment, whereas UP:C was
associated with anxiety. The type I h2 values for these relationships were much smaller than those for edema, indicating that the
Kidney International (2019) 95, 1209–1224

experience of disease appears to have more impact on HRQOL
than traditional quantitative laboratory biomarkers. Race,
ethnicity, and diagnosis were not associated signiﬁcantly with
HRQOL in either children or adults in the multivariable models.
Disease duration and HRQOL

Disease duration had no relationship to HRQOL in either
children or adults. We hypothesized that this could be because
of an interaction with disease activity, in which those subjects
with a short duration of disease were more likely to be
symptomatic. To test this, we created models with interaction
terms between worst edema severity and disease duration to
explain HRQOL, however, we found no statistically signiﬁcant interactions for any of the PROMIS scores. We then
tested whether disease duration had a different effect on
HRQOL across diagnostic categories, but even after stratifying
by diagnosis no signiﬁcant interactions were found.
Immunosuppression and HRQOL

Exposure to IST in the prior 60 days was not associated with
HRQOL in the multivariable models. To explore this
1213
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Figure 2 | Distribution of PROMIS domains in (a) children and (b) adults. Note that the direction of better versus worse scores differs
among domains and is indicated by arrows for each panel. HRQOL, health-related quality of life; PROMIS, Patient-Reported Outcomes
Measurement Information System. (Continued)

relationship further, we tested models with alternative IST
variables including exposure limited to the prior 30 days or
prior 7 days. Neither of those alternatives changed the results

1214

of the analysis compared with IST in the past 60 days.
Furthermore, we tested for a dose-response relationship by
operationalizing IST exposure as the number of days exposed

Kidney International (2019) 95, 1209–1224
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Figure 2 | (Continued)

to high-dose corticosteroids in the prior 60 days (deﬁned as
>40 mg/d prednisone equivalent in adults and >1 mg/kg/d in
children) as well as the average daily corticosteroid dose in the
prior 60 days (Supplementary Figure S1). Dose-dependent
IST variables were not associated with any HRQOL domain
in the multivariable model.
Kidney International (2019) 95, 1209–1224

In a ﬁnal sensitivity analysis, we tested if there was a difference in HRQOL by patients treated with corticosteroids
alone compared with patients not on immunosuppression
(Figure 6). Use of corticosteroids was not associated with
differences in any of the PROMIS domains in either children
or adults.
1215
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Figure 3 | The impact of any edema on PROMIS domain scores at
enrollment in the CureGN study. Plots of (a) children and (b) adults
show the adjusted linear regression coefﬁcients (b) from
multivariable models, with tails indicating lower and upper
conﬁdence limits. For ease of comparison, each b estimate has been
plotted as the negative of its absolute value, in which negative
numbers indicate a worse patient-reported outcome. The dashed
line denotes the minimally important difference from baseline. CI,
conﬁdence interval; HRQOL, health-related quality of life; PROMIS,
Patient-Reported Outcomes Measurement Information System.

DISCUSSION

This was a large study of HRQOL in primary glomerular
disease, and included cross-disease comparisons as well as
provided data in IgAN/IgAV and MN. In aggregate, adults
reported relatively worse HRQOL scores in multiple domains
compared with children. We found few differences in HRQOL
between diseases. Edema had the strongest association with
HRQOL in children and adults. It had a signiﬁcant association
with all domains measured, and accounted for the greatest
amount of variance observed in HRQOL scores. This ﬁnding
complements prior work that found edema was associated
with poor PROMIS scores in children with chronic kidney
disease.12 Edema is one of the major symptoms experienced by
patients with glomerular disease and can affect patients
adversely in a variety of ways. The severity of edema may be a
correlate of disease severity, but we found that patient-reported
edema severity explained more variance in HRQOL than
traditional biological markers of disease severity such as eGFR
or proteinuria. Furthermore, edema in this study was patientreported, rather than clinician-reported, so correlation with
1216
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Figure 4 | Worst edema severity by diagnosis in (a) children and
(b) adults. FSGS, focal segmental glomerulosclerosis; IgAN, IgA
nephropathy; IgAV, IgA vasculitis; MCD, minimal change disease;
MN, membranous nephropathy.

worse HRQOL in other domains might be expected (i.e., a
patient’s subjective report of edema may represent more than
just simple interstitial ﬂuid expansion, but a broader subjective
impression of the disease experience).
Female sex was associated with worse anxiety and fatigue
in children and adults, worse global assessment of physical
health in adults, and worse composite HRQOL scores in both
age groups. The overall variance explained was minimal, and
dwarfed by the effect of edema. However, worse HRQOL
experienced by females has been noted previously in studies
of chronic kidney disease, rheumatologic disease, and a variety of other conditions.13–15 Our study extrapolated this
relationship to primary glomerular diseases and highlights the
importance of addressing gender disparities in disease outcomes both by personalizing treatment approaches as well as
understanding systematic factors that might be at play.
A number of important variables were not associated
signiﬁcantly with HRQOL after multivariable adjustment. In
children, diagnosis, disease duration, proteinuria, and eGFR
did not have a signiﬁcant effect on any of the HRQOL
Kidney International (2019) 95, 1209–1224
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Table 3 | Final pediatric multivariable models for predicting HRQOL across measured domains

Global assessment of health
Worst edema
Weight
Underweight
Normal weight
Overweight
Obese
Anxiety
Total edema
Sex (female vs. male)
Fatigue
Face edema
Hand edema
Sex (female vs. male)
Weight
Underweight
Normal weight
Overweight
Obese
Mobility
Whole-body edema
Arm edema
Leg edema
Weight
Underweight
Normal weight
Overweight
Obese
Composite
Worst edema
Arm edema
Sex (female vs. male)
Weight
Underweight
Normal weight
Overweight
Obese

b (95% CI)

P

–1.5 (–2.1 to –0.9)

<0.001
<0.001
0.13
Ref
0.54
<0.001

Model h2

Type I h2

Type III h2

VIF

0.06
0.03

0.06
0.03

1.06

0.09
–4.6 (–10.5 to 1.3)
Ref
–0.7 (–3.0 to 1.6)
–3.8 (–5.7 to –1.9)

1.02
Ref
1.18
1.15
0.07

0.3 (0.2–0.4)
1.4 (0.2–2.6)

<0.001
0.02

5.8 (3.2–8.4)
7.9 (4.2–11.7)
3.1 (1.1–5.1)

<0.001
<0.001
0.002
0.01
0.09

0.06
0.01

0.06
0.01

1.01
1.01

0.09
0.04
0.02
0.02

0.03
0.03
0.02
0.02

1.24
1.27
1.03

0.17

–6.3 (–13.5 to 0.9)
Ref
1.0 (–1.7 to 3.8)
2.9 (0.6–5.2)

1.03
Ref
1.23
1.15

0.47
0.01
0.15

–4.9 (–8.6 to –1.2)
–4.6 (–9.0 to –0.2)
–3.7 (–6.1 to –1.4)
–1.5 (–7.3 to 4.2)
Ref
–0.5 (–2.6 to 1.6)
–2.8 (–4.6 to –1.0)

0.01
0.04
0.002
0.02
0.60
Ref
0.65
0.002

0.09
0.02
0.02
0.02

0.01
0.01
0.02
0.02

2.10
2.10
1.37
1.02
Ref
1.17
1.17

0.21
–1.9 (–2.6 to –1.2)
–6.9 (–11.2 to –2.6)
–2.5 (–4.2 to –0.8)
0.8 (–5.6 to 7.1)
Ref
–0.7 (–3.0 to 1.6)
–3.8 (–5.7 to –1.8)

<0.001
0.002
0.003
0.001
0.81
Ref
0.55
0.001

0.15
0.02
0.01
0.03

0.05
0.02
0.02
0.03

1.46
1.45
1.03
1.02
Ref
1.21
1.15

For each domain, a higher score means more of that item (e.g., higher anxiety scores imply worse anxiety, higher mobility scores imply better mobility). For the composite
score, higher is better. Model h2 ¼ overall h2 for the adjusted multivariable model; type I h2 ¼ model h2 in an unadjusted model of the variable by itself (i.e., the various type I
h2 values will sum to the model h2); type III h2 ¼ the change in the total model h2 after removing that variable from the model.
CI, conﬁdence interval; HRQOL, health-related quality of life; VIF, variance inﬂation factor.

domains or with the composite score. In adults, eGFR had a
minor impact on HRQOL, and diagnosis did not correlate
with any HRQOL domain.
The use of IST did not affect HRQOL in our adjusted
multivariable model. For our primary analyses, subjects were
categorized as having used IST if they had received it within
the past 60 days. We subsequently conducted sensitivity analyses using cut-off times of 30 and 7 days, as well as the
number of days on high-dose corticosteroids in the past 60
days, and still found no effect on HRQOL. It may be that the
average corticosteroid doses were too low in this population
to elicit detectable adverse effects. Most subjects had less than
0.5 mg/kg/d of prednisone equivalent averaged over 60 days
(Supplementary Figure S1). Another possible explanation for
these ﬁndings is that IST can have positive and/or negative
effects on HRQOL. There are well-known side effects to these
medications that certainly could have an adverse effect on
HRQOL, but they also have the potential to improve HRQOL
by treating the underlying disease and/or by providing
Kidney International (2019) 95, 1209–1224

optimism of a treatment beneﬁt. The effect of IST on HRQOL
likely depends on timing of therapy relative to changes in
disease status and is subject to confounding, making it challenging to elucidate a simple relationship.
We also examined whether disease duration was associated
with HRQOL. Prior work found that disease duration negatively impacted some domains of HRQOL in children with
active nephrotic syndrome.7 However, disease duration was
not found to have a signiﬁcant association with HRQOL in
children or adults after adjusting for other factors, including
after stratiﬁcation by diagnosis.
Our ﬁnding that HRQOL was not related to diagnosis was
unexpected but important. It suggests that among patients
with the diseases studied here, the impact of glomerular
disease on quality of life depends most on physical experience,
exempliﬁed by the presence of edema, rather than the underlying diagnosis. Our results, if conﬁrmed, have implications for how we should evaluate and manage patients.
Perhaps prioritizing control of edema (as reported by
1217
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Table 4 | Final adult multivariable models for predicting HRQOL across measured domains

b (95% CI)
Global assessment of physical health
Worst edema
Total edema
eGFR (per 30-unit change)
Sex (female vs. male)
Weight
Underweight
Normal weight
Overweight
Obese
Global assessment of mental health
Worst edema
Total edema
eGFR (per 30-unit change)
Anxiety
Worst edema
Hand edema
Genital edema
ln(UP:C) (per doubling)
Hematuria (yes vs. no)
Sex (female vs. male)
Fatigue
Worst edema
Hand edema
eGFR (per 30-unit change)
Sex (female vs. male)
Sleep impairments
Worst edema
Hand edema
Genital edema
eGFR (per 30-unit change)
Age (per 10-unit change)
Composite
Worst edema
Hand edema
Genital edema
Hematuria (yes vs. no)
Sex (female vs. male)

P

Model h2

Type I h2

Type III h2

VIF

0.26
0.01
0.02
0.01
0.02

0.02
0.02
0.02
0.01
0.02

3.52
3.48
1.02
1.02

0.32
–1.6
–0.3
1.1
–1.6

(–2.2 to –1.1)
(–0.4 to –0.2)
(0.7–1.6)
(–2.6 to –0.5)

–2.0 (–7.0 to 2.9)
Ref
–1.1 (–2.4 to 0.1)
–3.1 (–4.3 to –1.9)

<0.001
<0.001
<0.001
0.002
<0.001
0.43
Ref
0.08
0.02

–0.7 (–1.3 to –0.1)
–0.3 (–0.5 to –0.2)
0.8 (0.3–1.3)

0.02
<0.001
<0.001

1.02
Ref
1.04
1.01
0.15
0.12
0.02
0.01

0.01
0.02
0.01

3.48
3.47
1.01

0.07
0.01
0.01
0.01
0.01
0.01

0.01
0.01
0.01
0.01
0.01
0.02

1.74
1.57
1.28
1.12
1.04
1.04

0.20
0.02
<0.01
0.01

0.08
0.02
<0.01
0.01

1.49
1.49
1.01
1.03

0.11
0.02
0.01
<0.01
0.01

0.03
0.02
0.01
0.01
0.01

1.61
1.52
1.27
1.23
1.24

0.17
0.03
0.01
<0.01
0.01

0.04
0.02
0.01
0.01
0.01

1.62
1.55
1.28
1.03
1.01

0.12
0.6
2.1
2.2
0.4
2.5
2.1

(0.3–1.0)
(0.9–3.5)
(0.3–4.1)
(0.1–0.7)
(1.0–4.0)
(1.1–3.0)

0.001
0.001
0.02
0.01
0.001
<0.001

2.1
3.6
–0.5
2.2

(1.7–2.5)
(2.1–5.1)
(–1.0 to –0.1)
(1.1–3.3)

<0.001
<0.001
0.04
<0.001

1.1
3.1
2.4
–0.6
–0.6

(0.7–1.4)
(1.7–4.4)
(0.6–4.3)
(–1.1 to –0.2)
(–0.9 to –0.3)

<0.001
<0.001
0.01
0.009
<0.001

–1.6
–3.8
–3.4
–2.5
–2.2

(–2.0
(–5.3
(–5.5
(–4.1
(–3.2

–1.2)
–2.3)
–1.2)
–0.8)
–1.1)

<0.001
<0.001
<0.001
0.003
<0.001

0.23

0.15

0.22
to
to
to
to
to

For each domain, a higher score means more of that item (e.g., higher global assessment scores imply better health, higher anxiety scores imply worse anxiety). For the
composite score, higher is better. Model h2 ¼ overall h2 for the adjusted multivariable model; type I h2 ¼ model h2 in an unadjusted model of the variable by itself (i.e., the
various type I h2 values will sum to the model h2); type III h2 ¼ the change in the total model h2 after removing that variable from the model.
CI, conﬁdence interval; HRQOL, health-related quality of life; VIF, variance inﬂation factor.

patients) will help us to have a more meaningful and positive
effect on the disease experience. In addition, our results
indicate that patient-reported edema may be an important
outcome to assess systematically and routinely in both clinical
practice and in trials of new therapies.
Ideally, when determining the domains most relevant
and important to assess with a PRO instrument for a given
disease, input from the target population is considered an
essential step to establish content validity, and generally is
elicited via qualitative research.16,17 Of note, a recently
published study using qualitative methods to develop PRO
measures in adults with FSGS18 was not available at the
time that the PRO assessment for CureGN was created.
However, concepts elicited and incorporated into this adult
FSGS PRO development work, including fatigue, edema,
and physical and emotional functioning, are included in
the CureGN HRQOL assessment. Unfortunately, current
literature does not exist for adults with the other primary
1218

glomerular diseases studied here (IgAN/IgAV, MN, and
MCD) or in children with the biopsy-proven diagnoses
included in CureGN. Future work of this type, including
concept elicitation and other qualitative work to guide
development of validated PRO measures, will be
important in optimizing our instruments to better characterize patient experience speciﬁc to primary glomerular
disease.
Our study had important limitations. As mentioned previously, this was a cross-sectional analysis because we
only analyzed data collected at the time of enrollment. Prospectively obtaining serial longitudinal measures of HRQOL
in the CureGN cohort should enrich our understanding of the
determinants of patient experience, particularly as participants experience disease relapse and remission and are
exposed to other treatments. This also will serve to diminish
the variance inherent in data from a single point in time, as
we present in the current study.
Kidney International (2019) 95, 1209–1224
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Figure 5 | PROMIS domain scores according to worst reported edema severity in (a) children and (b) adults. PROMIS, Patient-Reported
Outcomes Measurement Information System.

Any conclusions we can draw are limited by the instruments used. The HRQOL data collected in CureGN
includes items selected from PROMIS, and the selection of
domains and items relevant to nephrotic syndrome were
based on scant available prior literature. For some populations within CureGN there were no published data to
inform these decisions and in these cases selection was
based on expert clinical knowledge of the diseases, their
symptoms, and how we presumed they affect HRQOL. The
creation of the assessment used in CureGN, including the
relevant PROMIS items to evaluate HRQOL, was guided in
part by studies that evaluated PRO in pediatric populations
with nephrotic syndrome.7–9,19 However, there is less
literature available for adults,10,11 and essentially none for
MN or IgAN/IgAV. Furthermore, in an attempt to decrease
Kidney International (2019) 95, 1209–1224

the burden on study participants, the number of items
included in the assessment was minimized. For these reasons, it is likely that we have not captured all of the
pertinent domains and signals for these diseases. It bears
emphasizing that although the PROMIS data in CureGN
ideally reﬂect measures important to patients, these measures ultimately were chosen by the investigators during
the study design and not by the patients themselves, and
there may be discordance between the importance of
symptoms captured in measures selected by clinicianscientists versus by patients. Since its initiation, CureGN
has incorporated a patient advisory council, and the perspectives of this council may be useful in helping to optimize our collection of PRO going forward. However,
formal study of the patient perspectives in this population
1219

clinical investigation

PA Canetta et al.: HRQOL in glomerular disease

Figure 6 | The impact of corticosteroids on PROMIS domain scores at enrollment in the CureGN study. Plots of (a) children and (b)
adults show the unadjusted linear regression coefﬁcients (b), with tails indicating lower and upper conﬁdence limits. For ease of comparison,
each b estimate has been plotted as the negative of its absolute value, in which negative numbers indicate a worse patient-reported
outcome. Analyses were based on 420 children (75 treated with corticosteroids vs. 345 not treated with any immunosuppression) and 979
adults (119 treated with corticosteroids vs. 860 not treated with any immunosuppression). CI, conﬁdence interval; HRQOL, health-related
quality of life; IST, immunosuppressive therapy; PROMIS, Patient-Reported Outcomes Measurement Information System.

likely also is necessary, as has been performed in hemodialysis and kidney transplant populations.20,21
PROMIS items are calibrated to a reference population,
which is usually the US general population. We did not
emphasize the absolute deﬁcits in HRQOL in this study,
although they can be implied from the score distributions
(Figure 1). Although such comparisons are valuable from a
public health perspective, exploring them was outside the
scope of the study’s main focus of determining associations
with HRQOL within glomerular disease patients. In addition,
PROMIS domains are measured with separate items for
children and adults, and thus are not directly comparable
between those age groups. Establishing linkage methods to
allow reliable comparison of domains between age groups is
an important area of ongoing research.22
The interpretation of differences in PROMIS results is
subject to consideration of clinically meaningful and statistical criteria for the determination of minimally important
differences (MIDs). Clinically meaningful differences in
scores have been assessed by patients, parent caregivers, and
1220

clinicians for children with nephrotic syndrome as well as
other chronic pediatric conditions.23 In these populations,
MIDs consistently were found to be clinically meaningful
with a difference of 3 points in PROMIS scores. Statistical
approaches have been used to estimate MIDs from studies of
adults with health conditions, none of which included kidney
disease. These statistical approaches generated MIDs in speciﬁc populations ranging from 4 to 8.5.24,25 Future use of
PROMIS in clinical settings for adult patients with glomerular
disease will beneﬁt from the replication of the clinical MID
work completed for children. Statistically signiﬁcant differences in PROMIS are reported in this study as well as other
scientiﬁc works. A statistically signiﬁcant difference may be
considered useful when devising approaches to populations
rather than to individual patient management.
We did not identify a relationship between HRQOL and
several purported associated variables, including disease
duration and IST. We attempted to clarify this using several
sensitivity analyses as described, but the possibility of failing
to detect true relationships cannot be ruled out. Two other
Kidney International (2019) 95, 1209–1224
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possible issues that may have contributed to the lack of association of immunosuppressive therapies with HRQOL
include the low dose of corticosteroids in the majority of
adults and the small number of patients receiving other
(noncorticosteroid) therapies. It is worth highlighting the
substantial variability in HRQOL that remained unexplained
in the multivariable models. This emphasizes that much of a
patient’s experience of how these diseases impact quality of
life remains difﬁcult to quantify. Whether it is because our
instruments miss important aspects of disease, or whether
they inadequately assess those that we chose to examine, is a
critical area for future study. We speculate that the use of
longitudinal data examining HRQOL associations with
treatment exposures and response over time will be particularly informative.
In conclusion, patient-reported edema had the strongest
association with HRQOL in children and adults with primary
glomerular diseases, with clinically meaningful associations
with all measured domains. Edema is one of the major
symptoms experienced by patients with glomerular diseases
and can affect patients adversely in a variety of ways. Our
results indicate that patient-reported edema may be an
important outcome to assess more systematically and
routinely in both clinical practice and trials of new therapies.
This foundation of knowledge will be built on with future
analyses of HRQOL from longitudinal data in CureGN, as
well as other glomerular disease cohorts. Future research is
needed to more comprehensively identify and quantify the
key variables impacting HRQOL in primary glomerular disease, optimize their assessment, and incorporate these measures into clinical trials.

METHODS
Patients
The CureGN study was designed to recruit children and adults with a
diagnostic kidney biopsy within the past 5 years showing MCD,
FSGS, MN, or IgAN (including IgAV) from more than 60 sites across
the United States, as well as 2 sites in Canada and 1 in Italy (https://
curegn.org). Approximately 600 each of MCD, FSGS, and MN
participants and 650 IgAN/IgAV participants will be enrolled. Patients are ineligible if they have end-stage kidney disease, or any of
the following before their ﬁrst kidney biopsy: solid-organ or bone
marrow transplant, active HIV infection, hepatitis B or C infection,
diabetes mellitus, systemic lupus erythematosus, or active malignancy. Each participating site obtained approval from an institutional review board, and all patients and/or legal guardians of
children provided informed consent and, where age appropriate,
informed assent before enrollment in the study.
In the current study, we present enrollment data from all enrolled
patients in CureGN with a completed enrollment visit at the time of
analysis. During the in-person enrollment visit, demographics,
clinical characteristics, laboratory test results, and patient- and/or
parent proxy–reported outcomes measures were collected. Clinical
characteristics included duration of disease, family history of kidney
disease, medication history and current use, and comorbidities.
Local laboratory test results, including serum creatinine, serum albumin, hematuria, and the UP:C, were abstracted from clinic
Kidney International (2019) 95, 1209–1224
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records. Most recent laboratory values before enrollment as well as
those from the closest date before kidney biopsy were recorded.
Blood and urine samples also were collected at the enrollment visit
and processed centrally by the CureGN laboratory to measure serum
creatinine and protein in either 24-hour, morning void, or spot
urine. Data were extracted on October 24, 2017.
HRQOL data
HRQOL was assessed using measures selected from PROMIS.26 Each
PROMIS measure generates a T-score (mean, 50; SD, 10 in the
calibration population), where a higher score indicates higher levels
of the trait being measured (i.e., higher mobility score ¼ better
mobility; higher anxiety score ¼ worse anxiety). We used an MID of
3.0 units, which is likely a conservative estimate based on available
literature.23 Each question uses a common time frame of “the past 7
days”, and responses use a 5-item Likert scale from “never” to
“almost always” for the majority of domains. PROMIS was administered as a paper form using a ﬁxed number of items. These items
were chosen a priori during the design of the CureGN study by a
working group of clinician investigators, with the aim of measuring
domains broadly relevant to patients with glomerular disease while
balancing the time burden on study participants. Of note, pediatric
and adult PROMIS items are separate, thus domains are not directly
comparable and they are analyzed separately throughout. The choice
of domains was informed by prior work in pediatric nephrotic
syndrome; no prior work related to PROMIS in adult nephrotic
syndrome was available.19
Pediatric domains included the following: global assessment of
health (10-item short form), mobility (4-item custom form), fatigue
(10-item short form), and anxiety (single-item custom form). Adult
domains included the following: global assessment of physical and
mental health (10-item short form), sleep impairments (single-item
custom form), fatigue (7-item custom form), and anxiety (singleitem custom form).
The actual items administered are available in the Supplementary
Appendix.
Creation of composite HRQOL score
The composite child and adult HRQOL scores were created to
summarize HRQOL from the various domains into a single summative measure. This was calculated by ﬁrst reverse scoring PROMIS
domains as needed so that all domains were oriented in the same
direction (i.e., higher scores ¼ better HRQOL). Next, scores were
standardized to a mean of 0 and a SD of 1. These scores then were
averaged, and rescaled back to a mean of 50 and SD of 10.
Although many clinicians and researchers may want to consider
different aspects of HRQOL separately (given the context of a speciﬁc
clinical question), there are also other clinicians and researchers who
may want to consider a simple summary score that is representative
of quality of life more generally. One common approach to the
generation of composite scores is to combine scores that are
conceptually related (e.g., mental HRQOL vs. physical HRQOL).27
Although domain-speciﬁc scores are readily interpretable, clinically
meaningful composite scores have the advantage of being able to
increase the power to detect subtle treatment-related differences that
may be associated with improvements across multiple aspects of
HRQOL.28,29 Therefore, an overall composite score that reﬂected
HRQOL was generated for both children and adults. This was
calculated by ﬁrst reverse scoring PROMIS domains as needed so
that all domains were oriented in the same direction (i.e., higher
scores ¼ better HRQOL). Next, scores were standardized to a mean
1221
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of 0 and SD of 1. These scores then were averaged, and rescaled back
to a mean of 50 and SD of 10. Each individual domain thus was
equally weighted in the composite score.
Associations with HRQOL
Independent variables of interest included kidney biopsy diagnosis,
age, sex, race, ethnicity, obesity (body mass index > 30 in adults;
body mass index percentile >95 in children), UP:C, eGFR (as
measured by Bedside Schwartz in children30 and Chronic Kidney
Disease Epidemiology Collaboration formula (CKD-EPI) in
adults31), hematuria, rash (for IgAV only), immunosuppressive
therapy in the past 60 days (speciﬁcally corticosteroids, calcineurin
inhibitors, mycophenolate, cyclophosphamide, rituximab, or corticotropin gel), average corticosteroid dose in the past 60 days (mg/kg/
d of prednisone or equivalent), and disease duration in months
(measured as the time from the ﬁrst diagnosis of kidney disease to
the date of enrollment).
A particular variable of interest was the presence of edema at
baseline. Edema was self-reported by the participant on the PRO
form (Supplementary Appendix). Participants were directed to
report the location of edema from 8 different areas (whole body,
face, hands, arms, abdomen, genitalia, legs, feet), and to rate the
severity of each on a scale of 0 to 5 points where 0 ¼ absent and 5 ¼
worst imaginable. Analyses considered edema characterized in
several different ways: (i) any edema, (ii) location of edema, (iii)
worst reported edema severity, and (iv) total edema severity (i.e., the
sum of the 8 edema questions).
Statistical analysis
All analyses were stratiﬁed by age (<18 vs. $18 yr) given the
different PRO instruments for pediatric and adult patients. Categoric
variables are described using frequencies and percentages; continuous variables are described using medians and interquartile ranges.
A series of linear regression models were ﬁt to test for associations
with each HRQOL domain separately, including the composite
scores. Each independent variable listed earlier, including the various
edema variables, was tested. We also included interaction terms a
priori to test for subgroup variation in the effect of edema by therapy
(edema*IST) and in the effect of diagnosis by disease duration and
activity (disease*duration, disease activity*duration).
Any univariable association with HRQOL at a P value less than
0.20 entered a multivariable backward selection model. Variables
were removed in order of descending P value until all remaining
variables were statistically signiﬁcant at a P value less than 0.05. h2
values were taken from each regression to describe the proportion
of variance explained by the total model, as well as each individual
covariate (type I h2). Type III h2 values also were calculated for
each covariate, representing the reduction in the total model h2
after removal of that covariate. All analyses were conducted in
SAS v9.4 (SAS Institute Inc., Cary, NC).
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Table S9. Unadjusted linear regression results of pediatric PROMIS
composite.
Table S10. Unadjusted linear regression results of adult PROMIS
global assessment of physical health.
Table S11. Unadjusted linear regression results of adult PROMIS
global assessment of mental health.
Table S12. Unadjusted linear regression results of adult PROMIS
anxiety.
Table S13. Unadjusted linear regression results of adult PROMIS
fatigue.
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Supplementary Appendix.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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